275 related articles for article (PubMed ID: 11518732)
1. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo.
Dowd NP; Scully M; Adderley SR; Cunningham AJ; Fitzgerald DJ
J Clin Invest; 2001 Aug; 108(4):585-90. PubMed ID: 11518732
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis.
Belton O; Byrne D; Kearney D; Leahy A; Fitzgerald DJ
Circulation; 2000 Aug; 102(8):840-5. PubMed ID: 10952950
[TBL] [Abstract][Full Text] [Related]
4. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
McAdam BF; Catella-Lawson F; Mardini IA; Kapoor S; Lawson JA; FitzGerald GA
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):272-7. PubMed ID: 9874808
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo.
Buerkle MA; Lehrer S; Sohn HY; Conzen P; Pohl U; Krötz F
Circulation; 2004 Oct; 110(14):2053-9. PubMed ID: 15451781
[TBL] [Abstract][Full Text] [Related]
6. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
7. Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2.
Henrion D; Dechaux E; Dowell FJ; Maclour J; Samuel JL; Lévy BI; Michel JB
Br J Pharmacol; 1997 May; 121(1):83-90. PubMed ID: 9146891
[TBL] [Abstract][Full Text] [Related]
8. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice.
Praticò D; Tillmann C; Zhang ZB; Li H; FitzGerald GA
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3358-63. PubMed ID: 11248083
[TBL] [Abstract][Full Text] [Related]
9. Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine.
Gross GJ; Moore J
Pharmacology; 2004 Jul; 71(3):135-42. PubMed ID: 15161995
[TBL] [Abstract][Full Text] [Related]
10. Sodium salicylate inhibits prostaglandin formation without affecting the induction of cyclooxygenase-2 by bacterial lipopolysaccharide in vivo.
Giuliano F; Mitchell JA; Warner TD
J Pharmacol Exp Ther; 2001 Dec; 299(3):894-900. PubMed ID: 11714873
[TBL] [Abstract][Full Text] [Related]
11. Protective role of cyclooxygenase (COX)-2 in experimental lung injury: evidence of a lipoxin A4-mediated effect.
Scully M; Gang C; Condron C; Bouchier-Hayes D; Cunningham AJ
J Surg Res; 2012 Jun; 175(1):176-84. PubMed ID: 21944479
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-1 mediates the final stage of morphine-induced delayed cardioprotection in concert with cyclooxygenase-2.
Jiang X; Shi E; Nakajima Y; Sato S; Ohno K; Yue H
J Am Coll Cardiol; 2005 May; 45(10):1707-15. PubMed ID: 15893191
[TBL] [Abstract][Full Text] [Related]
13. COX-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts.
Shinmura K; Nagai M; Tamaki K; Tani M; Bolli R
Am J Physiol Heart Circ Physiol; 2002 Dec; 283(6):H2534-43. PubMed ID: 12388283
[TBL] [Abstract][Full Text] [Related]
14. Role of cyclooxygenase-2 in oleic acid-induced acute lung injury.
Gust R; Kozlowski JK; Stephenson AH; Schuster DP
Am J Respir Crit Care Med; 1999 Oct; 160(4):1165-70. PubMed ID: 10508803
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
Sun Y; Tang XM; Half E; Kuo MT; Sinicrope FA
Cancer Res; 2002 Nov; 62(21):6323-8. PubMed ID: 12414664
[TBL] [Abstract][Full Text] [Related]
16. The COX-2 inhibitor NS-398 causes T-cell developmental disruptions independent of COX-2 enzyme inhibition.
Xu H; Izon DJ; Loftin C; Spain LM
Cell Immunol; 2001 Dec; 214(2):184-93. PubMed ID: 12088417
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.
Totzke G; Schulze-Osthoff K; Jänicke RU
Oncogene; 2003 Sep; 22(39):8021-30. PubMed ID: 12970750
[TBL] [Abstract][Full Text] [Related]
18. Role of cyclo-oxygenase-2 induction in interleukin-1beta induced attenuation of cultured human airway smooth muscle cell cyclic AMP generation in response to isoprenaline.
Pang L; Holland E; Knox AJ
Br J Pharmacol; 1998 Nov; 125(6):1320-8. PubMed ID: 9863663
[TBL] [Abstract][Full Text] [Related]
19. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor.
Kearney D; Byrne A; Crean P; Cox D; Fitzgerald DJ
J Am Coll Cardiol; 2004 Feb; 43(4):526-31. PubMed ID: 14975458
[TBL] [Abstract][Full Text] [Related]
20. Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2.
Pidgeon GP; Tamosiuniene R; Chen G; Leonard I; Belton O; Bradford A; Fitzgerald DJ
Circulation; 2004 Oct; 110(17):2701-7. PubMed ID: 15492320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
